The presentation will include:

• Data showing the variability and lack of robust, durable responses in current immunotherapy trials with CAR-based treatments
• Characterization data demonstrating the variability in cAPI for some currently used immunotherapies
• The Excellos paradigm for addressing effector function, metabolic assessment, and donor cell repertoire characterization to identify preferred donors for optimal starting-material collection